


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT_{1A} receptor subtype wherein the disorder is depression selected from the group consisting of endogenous depression, major depression, melancholia and treatment resistant depression, which comprises administering to said patient a therapeutically effective amount of a carbostyryl compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal:



wherein the carbon-carbon bond between 3- and 4- positions in the carbostyryl skeleton is a single or a double bond.

2-19. (Cancelled)

20. (Previously presented) The method of claim 1 wherein the carbostyryl compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyryl.

21-32. (Cancelled).